secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0000899923-25-000103
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics Q3 revenue $205.7M (-4% YoY); GAAP net loss $0.29/sh, adj EPS $0.00; FY guidance reiterated
--------------------------------------------------------------------------------

- Q3 revenue $205.7M, down 4% YoY; flat excluding $8.1M in headwinds from UNH GeneSight coverage loss and EndoPredict divestiture.
- GAAP net loss $27.4M ($0.29 per share); adjusted EPS $0.00; adjusted EBITDA $10.3M.
- Hereditary cancer testing volume +11% YoY, revenue +3%; pharmacogenomics revenue -19% due to UnitedHealthcare coverage discontinuation.
- Gross margin 69.9%; cash and equivalents $145.4M as of Sept 30, 2025.
- Entered strategic collaboration with SOPHiA GENETICS for global liquid biopsy companion diagnostic development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992325000103/0000899923-25-000103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992325000103/mygn-20251103.htm
  HTML page:      https://secwatch.observer/filing/0000899923-25-000103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer